MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Amgen Inc

Fermé

SecteurSoins de santé

305.92 -0.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

300.07

Max

306.68

Chiffres clés

By Trading Economics

Revenu

-2.2B

627M

Ventes

586M

9.1B

P/E

Moyenne du Secteur

41.156

63.778

BPA

5.31

Rendement du dividende

3.06

Marge bénéficiaire

6.901

Employés

28,000

EBITDA

-517M

2.9B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.31% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.06%

2.39%

Prochains Résultats

1 mai 2025

Date du Prochain Dividende

6 juin 2025

Date du Prochain Détachement de Dividende

16 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

14B

167B

Ouverture précédente

306.18

Clôture précédente

305.92

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Amgen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 févr. 2025, 21:29 UTC

Résultats

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 oct. 2024, 20:18 UTC

Résultats

Amgen Posts Higher 3Q Sales on Strong Demand

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 févr. 2025, 21:02 UTC

Résultats

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Adj EPS $5.31 >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Rev $9.1B >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q EPS $1.16 >AMGN

4 févr. 2025, 21:01 UTC

Résultats

Amgen 4Q Net $627M >AMGN

28 janv. 2025, 10:30 UTC

Actualités

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 déc. 2024, 07:00 UTC

Résultats

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 déc. 2024, 15:04 UTC

Actualités

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 déc. 2024, 14:53 UTC

Actualités

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov. 2024, 12:00 UTC

Actualités

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov. 2024, 12:34 UTC

Actualités

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov. 2024, 12:00 UTC

Actualités

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 oct. 2024, 20:02 UTC

Résultats

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 oct. 2024, 20:02 UTC

Résultats

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 oct. 2024, 20:02 UTC

Résultats

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 oct. 2024, 20:02 UTC

Résultats

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct. 2024, 20:02 UTC

Résultats

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 oct. 2024, 20:01 UTC

Résultats

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 oct. 2024, 20:01 UTC

Résultats

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct. 2024, 20:01 UTC

Résultats

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Comparaison

Variation de prix

Amgen Inc prévision

Objectif de Prix

By TipRanks

8.31% hausse

Prévisions sur 12 Mois

Moyen 332.43 USD  8.31%

Haut 389 USD

Bas 280 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

11

Achat

6

Maintien

1

Vente

Score Technique

By Trading Central

305.71 / 315.18Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.